The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands

References

• Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103(2 Suppl 1):12-17
   Google Scholar
• Lips P, Cooper C, Agnusdei D, et al. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int 1999;10:150-160
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, van Staa T, Ariely R, et al. Excess mortality following hip fracture: a systematic, epidemiological review. Osteoporos Int 2009;20:1633-1650
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-382
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-739
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005;16:229-238
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002;17:1237-1244
   PubMed Web of Science ®Google Scholar
• Stevenson M, Lloyd Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160
   PubMed Web of Science ®Google Scholar
• Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 2007;18:711-719
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-928
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Yood RA, et al. Consequences of poor compliance with bisphosphonates. Bone 2007;41:882-887
   PubMed Web of Science ®Google Scholar
• Sheehy O, Kindundu CM, Barbeau M, et al. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int 2009;20:1583-1594
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJA, Erkens JA, Olson M, et al. Determinants of noncompliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 2008;24:1337-1344
   PubMed Web of Science ®Google Scholar
• Stevenson M, Davis S, Lloyd-Jones M, et al. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 2007;11:1-134
   PubMed Web of Science ®Google Scholar
• Johnell O, Jönsson B, Jönsson L, et al. Cost-effectiveness of alendronate (fosamax) for the treatment of osteoporosis and the prevention of fractures. Pharmacoeconomics 2003;21:305-314
   PubMed Web of Science ®Google Scholar
• Borgström F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006;17:996-1007
   PubMedGoogle Scholar
• Singer BR, McLauchlan GJ, Robinson CM, et al. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 1998;80:243-248
   PubMedGoogle Scholar
• Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 2000;11:669-674
   PubMed Web of Science ®Google Scholar
• Lofthus CM, Osnes EK, Falch JA, et al. Epidemiology of hip fractures in Oslo, Norway. Bone 2001;29:413-418
   PubMed Web of Science ®Google Scholar
• Lofthus CM, Frihagen F, Meyer HE, et al. Epidemiology of distal forearm fractures in Oslo, Norway. Osteoporos Int 2008;19:781-786
   PubMed Web of Science ®Google Scholar
• Osnes EK, Lofthus CM, Meyer HE, et al. Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 2004;15:567-574
   PubMed Web of Science ®Google Scholar
• Nurmi I, Narinen A, Lüthje P, et al. Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients. Arch Orthop Trauma Surg 2003;123:551-554
   PubMed Web of Science ®Google Scholar
• Statistisk sentralbyrå (Statistics Norway). 2006. Available at: www.ssb.no [Last accessed December 2007]
   Google Scholar
• Tilastokeskus (Statistics Finland). Kuolleisuus – ja eloonjäämislukuja. 2005. Available at: http://www.tilastokeskus.fi [Last accessed September 2007]
   Google Scholar
• Centraal Bureau voor de Statistiek (2006) Voorburg/Heerlen. Available at: http://www.cbs.nl [Last accessed May 2008]
   Google Scholar
• Olson M, Brereton N, Huels J, et al. Comparison of the cost-effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in the UK setting. Poster POS8 presented at the annual European congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, Ireland, 20-23 October, 2007
   Google Scholar
• National Institute for Health and Clinical Excellence. Final Appraisal Determination: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. 2007. Available at: http://guidance.nice.org.uk/page.aspx?o=437523 [Last accessed December 2009]
   Google Scholar
• Roche Products Ltd. Bonviva 3 mg/3 mL solution for injection in pre-filled syringe: Summary of product characteristics. 2006. Available at: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=17546 [Last accessed January 2008]
   Google Scholar
• Roche Products Ltd. Bonviva 150 mg film-coated tablets: Summary of product characteristics. 2006. Available at: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=16730 [Last accessed January 2008]
   Google Scholar
• Chesnut CH III, Skag A, Christiansen C. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249
   PubMed Web of Science ®Google Scholar
• Hujanen T. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2001, Stakes Aiheita 1/2003. Available at: http://www.stakes.fi/verkkojulkaisut/muut/Aiheita1-2003.pdf [Last accessed September 2007]
   Google Scholar
• Borgstrøm F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporotic-related fractures in Sweden. Osteoporos Int 2006;17:637-650
   PubMed Web of Science ®Google Scholar
• Meerding WJ, Mulder S, van Beeck EF. Incidence and costs of injuries in The Netherlands. Eur J Public Health 2006;16:272-278
   PubMedGoogle Scholar
• KOSTRA. Korrigerte brutto driftsutg., pleie i institusjon, pr. kommunal plass. 2006. Available at: http://www.ssb.no/kostra [Last accessed December 2007]
   Google Scholar
• Forbruksundersøkelsen 2003-2005. Available at: www.ssb.no/emner/05/02/fbu/tab-2006-09-11-01.html [Last accessed December 2007]
   Google Scholar
• Oostenbrink JB, Bouwmans CAM, Koopmanschap MA. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidzorg. Geactualiseerde versie 2004. Diemen, The Netherlands: College voor zorgverzekeringen, 2004
   Google Scholar
• SLD price database. Helsinki, Finland: Finnish Pharmaceutical Data Ltd, 2008
   Google Scholar
• Stevenson MD, Davis SE, Kanis JA. The hospitalisation costs and out-patient costs of fragility fractures. Women's Health Med 2006;3:149-151
   Google Scholar
• Norwegian Medicines Agency Database. 2008. Available at: http://www.legemiddelverket.no/custom/Preparatsok/prepSearch____80333.aspx [Last accessed July 2008]
   Google Scholar
• Z-Index bv. Z-Index Taxe, December 2008
   Google Scholar
• Den norske legeforening. Normaltariff of privat spesialistpraksis 2007-2008. Oslo, Norway: Den norske legeforening. 2007. Available at: http://www.legeforeningen.no/assets/Normaltariffen_2007.pdf [Last accessed December 2007]
   Google Scholar
• Ministry of Social Affairs and Health. Guidelines for preparing a health economic evaluation. Annex to decree 1111/2005. Helsinki, Finland: Ministry of Social Affairs and Health, 2005
   Google Scholar
• Ministry of Social Affairs and Health. Guidelines for preparing a health economic evaluation. Annex to decree 201/2009. Helsinki, Finland: Ministry of Social Affairs and Health, 2009
   Google Scholar
• College voor zorgverzekeringen. Guidelines for pharmacoeconomic research in The Netherlands (updated version). Diemen, The Netherlands: College voor zorgverzekeringen, April 2006
   Google Scholar
• Kanis JA, Johnell O, Oden A. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004;15:20-26
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998;8(Suppl 4):S7-S80
   Google Scholar
• Kwaliteitsinstituut voor de Gezondheidszorg CBO. Behandeling en preventie van coronaire hartziekten door verlaging van de plasmacholesterolconcentratie. Consensus cholesterol tweede herziening. Utrecht, The Netherlands: CBO, 1998
   Google Scholar
• Council for Public Health and Health Care. Sensible and sustainable care. Zoetermeer, The Netherlands: Council for Public Health and Health Care, 2006
   Google Scholar
• FRAX® WHO Fracture risk assessment tool: Charts of the FRAX® tool. Available at: http://www.sheffield.ac.uk/FRAX/charts.jsp [Last accessed 17 September 2010]
   Google Scholar
• Kanis JA, Stevenson M, McCloskey EV. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2007;11:1-231
   Web of Science ®Google Scholar
• Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20:291-297
   PubMed Web of Science ®Google Scholar
• Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-245
   PubMed Web of Science ®Google Scholar
• Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922-928
   PubMed Web of Science ®Google Scholar
• van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006;22:1757-1764
   PubMed Web of Science ®Google Scholar
• Meijer WM, Penning-van Beest FJA, Olson M, et al. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Curr Med Res Opin 2008;24:3217-3222
   PubMed Web of Science ®Google Scholar
• Schousboe JT, Nyman JA, Kane RL, et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005;142:734-741
   PubMed Web of Science ®Google Scholar
• Goeree R, Blackhouse G, Adachi J. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin 2006;22:1425-1436
   PubMed Web of Science ®Google Scholar
• Sheehy O, Kindundu CM, Barbeau M, et al. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 2009;20:1369-1376
   PubMed Web of Science ®Google Scholar
• McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41:122-128
   PubMed Web of Science ®Google Scholar
• Saag K, Lindsay R, Kriegman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007;40:1238-1243
   PubMed Web of Science ®Google Scholar
• Novartis Europharm Ltd. Aclasta: summary of product characteristics. 2008. Available at: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=18171 [Last accessed December 2008]
   Google Scholar
• Lyles KW, Colón-Emeric CS, Magaziner JS. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-1809
   PubMed Web of Science ®Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-561
   PubMed Web of Science ®Google Scholar
• Kado DM, Browner WS, Palermo L, et al. for the Study of Osteoporotic Fractures Research Group. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med 1999;159:1215-1220
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;15:108-112
   PubMed Web of Science ®Google Scholar